Get 40% Off
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks!Unlock list

Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'

Published 17/01/2024, 13:22
© Reuters.  Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. "I think that Stephane Bancel is the real deal," he added.

Cramer recommended holding onto BioNTech SE (NASDAQ: BNTX). "I don’t understand why it’s so inexpensive," he noted.

When asked about Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH), he said, "This was part of one of these situations where once, once the pandemic was over, people just don’t want it anymore. I don’t know. I mean, to me, I want you in Becton, Dickinson and Company (NYSE: BDX), let’s put it that way. You won’t have that kind of up and down thing."

Don’t forget to check out our premarket coverage here

The "Mad Money" host said Pan American Silver Corp. (NYSE: PAAS) is the "best one" of the silver companies.

When asked about Starwood Property Trust, Inc. (NASDAQ: STWD), he said, "That’s Barry Sternlicht, and, you know what, I’m willing to take his dividend and wait for that turn."

"Just buy it," Cramer said about Lockheed Martin Corporation (NYSE: LMT).

Price Action: Shares of Lockheed Martin fell 1.2% to close at $457.84, while Starwood Property Trust fell 1.7% to $20.46 on Tuesday. Pan American Silver fell 5.2% to settle at $14.68, while Becton, Dickinson shares slipped 0.5% to close at $235.00 during Tuesday’s session. Amphastar Pharmaceuticals gained 2.4% to $55.50, while BioNTech fell 3.9% to settle at $99.57. Moderna shares declined 3.6% to close at $102.16 on Tuesday.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Now Read This: Nvidia, CrowdStrike And 2 Other Stocks Insiders Are Selling

Photo: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.